Breaking News, Trials & Filings

BioMarin Receives $15M Milestone from Pfizer

Triggered by the FDA's approval of Talzenna® (talazoparib) for the treatment of various forms of breast cancer

BioMarin Pharmaceutical Inc. announced their earning of a  $15 million in milestone payments from Pfizer Inc. These milestone payments were triggered by the U.S. Food and Drug Administration’s approval of Talzenna® (talazoparib) for the treatment of adult patients with deleterious or suspected deleterious germline BRCA (gBRCA)-mutated, HER2-negative locally advanced (LA) or metastatic breast cancer (MBC).  Patients are selected for therapy based on an FDA-approved companion diagnostic. These ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters